Yahoo Web Search

  1. Yahoo Finance Results

  2. Assessing Merck & Co Inc’s (NYSE:MRK) past track record of performance is a useful exercise for investors. It allows us to understand whether the company has met or exceed ...

  3. When it comes to pharmaceuticals, few names are as renowned as Merck & Co., Inc. (NYSE:MRK). After a disappointing third quarter earnings report, Merck stock plummeted ...

    62.54+3.88 (+6.61%)

    at Tue, Jan 16, 2018, 2:18PM EST - U.S. Markets close in 1 hr 42 mins

    Nasdaq Real Time Price

    • Open 61.75
    • High 63.78
    • Low 61.25
    • Prev. Close 58.66
    • 52 Wk. High 66.80
    • 52 Wk. Low 53.63
    • P/E 60.54
    • Mkt. Cap 170.3786B
  4. Merck's Keytruda Gets Approved for Bladder Cancer in Japan

    Zacks via Yahoo FinanceJan 03 20:42 PM

    Merck & Co., Inc. MRK announced that its anti-PD-1 therapy, Keytruda (pembrolizumab), has been approved in Japan for previously-treated patients with urothelial carcinoma ...

  5. Hampton, NJ-based Celldex Therapeutics, Inc. CLDX is a biopharmaceutical company developing immunotherapy technologies and other cancer-targeting biologics. The company is developing ...

  6. The drug is approved for several cancer indications including non-small cell lung cancer in combination with Eli Lilly's (LLY) Alimta and carboplatin. Price Merck & Company, Inc. Price | Merck & Company, Inc.

  7. SELLAS Life Sciences Group, Inc. Nasdaq:SLS) (SELLAS Inc. today announced that the proposed merger of the businesses of SELLAS Life Sciences Group Ltd. (SELLAS Ltd.) and Galena Biopharma, Inc.

  8. BOSTON, Dec. 29, 2017 /PRNewswire/ -- Juniper Pharmaceuticals (JNP), a diversified healthcare company focused on women's health, today announced that Juniper Pharma Services co-founder ...

  9. Furthermore, increasing number of patent expirations and entry of generic drugs in the market are expected to increase the demand for infectious disease therapeutics due to their low prices.

  10. This could indicate that investors who seek to profit from falling equity prices are not currently targeting MRK. Index (PMI) data, output in the Healthcare sector is rising.

  11. Biotechnology Market - Expected to Reach $727 Billion by 2025

    PR Newswire via Yahoo FinanceDec 27 16:30 PM

    The emergence of certain key themes in the biotechnology market is expected to drive growth in this industry to a lucrative extent. These key themes include regenerative medicine and genetics ...

  1. Ads
    related to Merck & Co., Inc